Introduction
Systemic lupus erythematosus (SLE) is an autoimmune disease which can involve multiple organs. It is generally thought that aberrant clearance of apoptotic cells plays an important role in the pathogenesis. When apoptotic cells are not cleared efficiently, they can turn into necrotic cells which lose their structural integrity and release several potential autoantigens [1, 2] . Exposure of these autoantigens to immune cells may lead to autoantibody production. The autoantibodies are used as serological markers in diagnosing SLE and during follow-up to predict disease activity. Several disease-specific autoantibodies have been documented in SLE; in particular, anti-double-stranded DNA (anti-dsDNA) and anti-Sm (anti-Smith), both anti-nuclear antibodies (ANA), are of diagnostic value [2] .
High mobility group box 1 (HMGB1) is a nuclear protein which can act as a damage-associated molecular pattern when released into the extracellular milieu [3] . The molecule consists of three separate domains: box A, box B and an acidic tail. Both boxes A and B are important for the DNA binding function of the molecule. HMGB1 can be released after cell activation, damage, apoptosis or necrosis, and has been implicated in the pathogenesis of several diseases, including SLE [4] . It has been shown that serum and urinary levels of HMGB1 are increased in SLE, and correlate with disease activity [5] [6] [7] . Released HMGB1 can have different functions depending on the redox status of HMGB1. For cytokine activity of HMGB1, cysteines C23 and C45 in box A must form a disulphide bond while cysteine C106 in box B must be in the thiol state. HMGB1 has chemoattractant properties when all three cysteines are reduced [8] . Extracellular HMGB1 can bind to several receptors, including Receptor for Advanced Glycation End products (RAGE) and Toll-like receptor 4 (TLR-4), the binding sites for which are located in the box B domain [3] . Recombinant box A can serve as a competitive antagonist for HMGB1 by binding to RAGE and can therefore inhibit HMGB1 activity [3] .
Autoantibodies against HMGB1 have been observed in patients with SLE [5, [9] [10] [11] . The clinical and/or pathological relevance of anti-HMGB1 antibodies is unclear, but their presence can interfere with the detection of HMGB1 in enzyme-linked immunosorbent assay (ELISA) systems [5, 12] . For SLE, we have reported previously that anti-HMGB1 antibody levels correlate with serum HMGB1 levels, disease activity and anti-dsDNA levels, suggesting that these autoantibodies may play a role in disease pathogenesis [5] . Opposing effects of anti-HMGB1 antibody treatment on disease progression were demonstrated in two different lupus mouse models [13, 14] . In other disease models, including rheumatoid arthritis (RA), positive effects have been reported of anti-HMGB1 treatment on disease progression [15] [16] [17] [18] .
As studies with anti-HMGB1 antibody treatment showed conflicting results, recombinant box A might be a better treatment option in SLE than box A, which is a competitive antagonist for HMBG1 and inhibits HMGB1 activity. For example, it has been shown that interaction between RAGE and HMGB1 can lead to interferon (IFN)-a production, which is important in the pathogenesis of SLE [19] . Perhaps this pathway can be blocked using recombinant box A. Furthermore, treatment with box A has shown beneficial effects in mouse models of sepsis [20] and arthritis [17, 21] . However, a previous study demonstrated anti-HMGB1 antibodies that recognize box A in sera from SLE patients [10] . These antibodies might interfere with the working mechanism of recombinant box A and make this a less feasible treatment option for SLE. As this was a small study and did not investigate the clinical relevance of these antibodies, we sought to investigate the reactivity to box A in a larger cohort of SLE patients. Therefore, in the present study we investigated autoantibodies to box A in SLE patients, healthy controls (HC) and disease controls and assessed possible associations between anti-box A levels and disease characteristics.
Materials and methods

Patients and controls
Eighty-six SLE patients and 44 age-and sex-matched HC were included. SLE patients fulfilled the American College of Rheumatology (ACR) criteria for SLE [22] . Twentyeight patients diagnosed with primary Sj€ ogren's syndrome (SjS) fulfilling the ACR-EULAR classification criteria, and 32 patients with RA fulfilling the ACR, criteria were included as disease controls. The study was approved by the Institutional Review Board of the UMCG and informed consent was obtained from all patients and HC. Disease activity at the time of blood sampling was assessed using the SLEDAI (SLE Disease Activity Index) for SLE patients [23] ; disease activity at the time of blood sampling was assessed using the EULAR Sj€ ogren's Syndrome Disease Activity Index (ESSDAI) for SjS patients [24] and RA disease activity was assessed using the Disease Activity Score 28 tender and swollen joint count (DAS28) [25] . Serum samples were collected between 2001 and 2013 and stored at 2208C until analysis. Of these 86 patients, 47 outpatients with SLEDAI 4 were included in the quiescent patient group and another 39 patients with active disease (SLEDAI ! 5) were selected retrospectively. Further clinical data and medication use was obtained from medical records. Characteristics of all patients and controls are summarized in Table 1 , and characteristics of the disease controls in Table 2 . From a small subgroup of the 39 active SLE patients (n 5 21) samples were available during active disease and during subsequent remission (4-12 months later). The characteristics of these patients are described only in the active group (see Table 1 ).
Levels of anti-dsDNA, anti-citrullinated peptide antibodies (ACPA), anti-SSA and anti-SSB were measured by EliA assay (ThermoFisher Scientific, Nieuwegein, the Netherlands). Total IgG, C-reactive protein (CRP), serum creatinine and complement factors (C3, C4) were determined by routine techniques. IgM rheumatoid factor was measured by an in-house ELISA, as described previously [26] .
Detection of anti-box A and anti-box B antibodies by ELISA
Antibodies directed against boxes A and B were detected using in-house ELISA. Costar plates were coated overnight with 1 mg/ml recombinant boxes A or B (HMGBiotech Srl, Milan, Italy). After blocking [with phosphate-buffered saline (PBS) 1 2% bovine serum albumin (BSA)], serum samples were diluted in incubation buffer (PBS 1 1% BSA) and were added in four dilutions (1 : 50, 1 : 150, 1 : 450 and 1 : 1350). Detection of antibodies was performed with mouse anti-human IgG-horseradish peroxidase (HRP) (Southern Biotech, Birmingham, AL, USA) for 30 min at room temperature. Bound antibodies were detected with 3,3',5,5'-tetramethylbenzidine dihydrochloride and H 2 O 2 ; the reaction was stopped with 2M H 2 SO 4 . Absorbance was measured at 450 nm using a microplate spectrophotometer and concentrations were calculated with Softmax software. Levels of anti-box A were calculated against a standard curve using serum of a SLE patient with high anti-box A levels and expressed as arbitrary units (AU).
Detection of anti-HMGB1 antibodies by ELISA
Anti-HMGB1 antibodies were measured using in-house ELISA. Greiner Bio-one plates were coated for at least 48 h with 1 mg/ml recombinant HMGB1 (Sigma, St Louis, MO, USA). After blocking with BSA, serum samples were diluted and were added in duplicate (1 : 100) to both coated and uncoated (PBS/BSA only) wells to correct for unspecific binding. Detection of antibodies was performed with goat anti-human IgG-HRP (Bethyl Labs, Montgomery, TX, USA; A80-104P). Afterwards, measurement of bound antibodies was performed as described above.
Statistical analysis
Data are presented as median (range) unless stated otherwise. Positivity was determined as upper 95% percentile of the HC values. Statistical calculations were performed using SPSS version 22 (SPSS Inc., Chicago IL, USA). Differences between patients and controls were calculated using the Mann-Whitney test. Paired samples were compared using Wilcoxon's signed-rank test. The KruskalWallis test was used for differences between groups larger than two. Spearman's rank correlation was used for correlations and for non-continuous variables a v 2 test was used. P-values < 0Á05 were considered significant.
Results
Anti-box A in SLE patients, disease controls and HC
Compared to HC, anti-box A levels were increased significantly in quiescent (P < 0Á001) and active SLE patients (P < 0Á001, Fig. 1a ). There was also a significant increase in anti-box A levels in active patients compared to quiescent patients (P < 0Á01, Fig. 1a) . Furthermore, anti-box A levels were increased significantly in SLE patients compared to patients with either RA or SjS (P < 0Á001, Fig. 1b) .
Sensitivity, specificity, positive predictive value and negative predictive values were calculated for anti-box A antibodies. Percentage positivity was defined as above the 95% percentile of the HC values. Anti-box A showed a sensitivity of 54 and 72% for quiescent and active patients, respectively, with a specificity of 95% in both patient groups compared to HC. Anti-box A antibodies had a specificity of 93% for SLE, based on the values from the disease controls (RA and SjS). Using the values of the disease controls, positive predictive value was calculated as 0Á93 and negative predictive value as 0Á63.
Associations between anti-box A with clinical and serological parameters
To assess whether anti-box A antibodies are associated with disease parameters, anti-box A levels were analysed in relation to clinical and serological parameters (Table 3) . Antibox A was correlated positively with SLEDAI (rho: 0Á38, P < 0Á001) and anti-dsDNA levels (rho: 0Á47, P < 0Á001). Furthermore, anti-box A was associated negatively with complement C3 (rho: 20Á31, P < 0Á05) and weakly with total IgG levels (rho: 0Á25, P < 0Á05). No significant correlations between complement C4, disease duration, CRP, IgM rheumatoid factor (RF) or creatinine and anti-box A levels were observed (Table 3) .
To investigate whether positivity of anti-box A antibodies was associated with specific organ involvement, patients were divided according to ACR criteria. Skin involvement was defined as positivity for either malar rash, discoid rash, photosensitivity or oral ulcers. There was no relation with nephritis or skin involvement or any other ACR criteria for anti-box A. Increased levels of anti-box A antibodies were present in the majority of patients with either nephritic (16 of 22 5 73%) and non-nephritic exacerbations (12 of 17 5 71%).
Possible effects of medication were investigated by stratifying patients into the following groups: no medication, immunosuppressive therapy (including prednisolone, mycophenolate mofetil, cyclophosphamide, azathioprine or combinations) and hydroxychloroquine only. No effect of therapy was observed on levels of IgG anti-box A or regarding positivity. Subanalysis on the effect of therapy also revealed no difference when patients were divided further based on active or quiescent disease.
Levels of anti-box A antibodies during and after active disease
Anti-box A levels were compared during active and subsequent quiescent disease (3-12 months later) in a subset (n 5 21) of SLE patients. Anti-box A levels were decreased significantly after active disease (P < 0Á01) (Fig. 2a) . Anti-box A levels increased after exacerbation in only three patients. For comparison, anti-dsDNA levels are shown in Fig. 2b in these patients during active and quiescent disease.
Levels of anti-HMGB1 and anti-box B antibodies in SLE patients and HC
Levels of anti-HMGB1 antibodies and anti-box B antibodies were also investigated in the same cohort of SLE patients and HC (Fig. 3) . Compared to HC, IgG anti-HMGB1 levels and anti-box B were increased significantly in quiescent and active SLE patients (Fig. 3a,b) . No significant differences were found between quiescent and active patients regarding anti-HMGB1 levels (Fig. 3a) . Active patients had higher levels of anti-box B compared to quiescent patients (P < 0Á05).
Sensitivity of IgG anti-HMGB1 in quiescent and active patients was 40 and 48%, respectively, while specificity was 93% for both. Anti-box B demonstrated a sensitivity of 25 and 41% in quiescent and active patients, respectively, with a specificity of 95% for both.
Combining the data from both anti-box A and anti-box B antibodies the following categories could be generated: negative for both anti-box A and anti-box B (n 5 25), positive for anti-Box A only (n 5 33), positive for anti-box B only (n 5 8) or positive for both (n 5 20). This indicates that reactivity to box A is most frequently present, either alone or in combination. Furthermore, there was a significant correlation between anti-box A and anti-box B antibodies (rho 5 0Á34, P < 0Á001), and anti-box A and anti-HMGB1 antibodies (rho 50Á35, P < 0Á001) in all SLE patients.
Discussion
In this study, we demonstrated that anti-box A antibodies are associated with SLEDAI, anti-dsDNA and associated negatively with complement C3 levels. Moreover, anti-box A antibodies displayed high specificity for SLE compared to HC and disease controls.
Previous studies have also demonstrated increased anti-HMGB1 levels in SLE patients [5, [9] [10] [11] , and in a small study more specific antibodies directed to box A [10] . In this study it was shown that through epitope mapping multiple HMGB1 epitopes were recognized in SLE sera, with the major epitope mapping box A. Our study confirm these data in a larger cohort. Moreover, when the data of antibodies directed against box A and box B domains were analysed, it was demonstrated that reactivity to box A was present most frequently, either alone or in combination with reactivity to box B. This indicates that box A is recognized predominantly as an autoantigen.
Our data indicate that sensitivity of antibodies directed to anti-box A was similar to the sensitivity of anti-dsDNA in active and quiescent SLE patients [27, 28] . Moreover, the 
Ig 5 immunoglobulin; n.s. 5 not significant; CRP 5 C-reactive protein. prevalence of increased levels of anti-box A during nephritis was equal to the prevalence during non-nephritic exacerbations, while anti-dsDNA levels are increased more often during nephritis compared to non-nephritic exacerbations, indicating that anti-box A antibodies might be a better marker during non-nephritic exacerbations compared to anti-dsDNA. These results should be validated in a larger cohort of SLE patient with a head-to-head comparison. Furthermore, whether an increase in anti-box A will predict an exacerbation and whether anti-box A might serve as an additional biomarker next to anti-dsDNA should be investigated further in prospective longitudinal studies.
As mentioned previously, HMGB1 consists of boxes A and B, and also of a C-acidic tail and a linker region, which plays a role in binding to RAGE. Box A is the DNA binding domain of the molecule, but can also serve as a competitive antagonist of HMGB1, and several studies in animal models have shown beneficial effects of box A on disease progression [21, 29] . As the antibodies in the majority of SLE patients (62%) predominantly recognized box A, this might interfere with box A as a therapeutic option. It might be reasoned that the antibodies which recognize box A will bind to box A itself, and thereby form complexes. Therefore, box A might not be a feasible treatment option in SLE, as the antibodies present recognize box A and might interfere with the treatment. However, this is hard to predict, and should be investigated in a lupus mouse model. Using sRAGE, which is a decoy receptor of HMGB1, good results were obtained in reducing lupus nephritis in a mouse model [30] .
Why anti-box A levels are increased specifically during active disease is unclear, but this may relate to the various post-translational modifications that HMGB1 can undergo, influencing its function. As mentioned previously, cytokine activity of HMGB1 is dependent upon the disulphide bond of cysteines C23 and C45 in box A, while cysteine C106 in box B must be in the thiol state [31, 32] . Antibodies to box A can inhibit the cytokine activity of HMGB1, as has been demonstrated previously [8] . An increase in circulating HMGB1 has been demonstrated in active SLE [5] , and it has been observed in a small study that oxidized HMGB1 is present in active SLE [33] . As oxidation may generate neo-epitopes in the HMGB1 molecule, this may promote autoimmune responses. The disulphide bond upon which cytokine activity is dependent is located in box A, therefore it could be that an increase in the cytokine form of HMGB1 leads subsequently to an increase in autoantibodies that recognize box A. In this respect, more detailed mapping of the epitopes recognized by the anti-HMGB1 autoantibodies may be helpful to reveal whether epitope specificities exist that potentially impact the disease course.
In conclusion, antibodies to box A had a high sensitivity and specificity for SLE, especially during active disease, reflected by the fact that anti-box A was associated positively with SLEDAI and anti-dsDNA and negatively with complement C3. Moreover, increased levels of anti-box A antibodies were present in the majority of patients with either nephritic or non-nephritic exacerbations, and especially in the latter group even more often compared to the presence of increased anti-dsDNA. Taken together, these results indicate that anti-box A might be an interesting new biomarker in the diagnosis and follow-up of SLE patients.
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